Skip to content
France
-
Valneva to close Nantes facility, centralizing R&D in Vienna following lower sales forecast
The closure announcement follows Valneva’s financial results for the first nine months of 2025, which revealed mixed performance.
-
Axoltis Pharma secures USD20.9 million in series A funding to advance ALS drug development
The total USD20.9 million funding will be divided into two tranches, with the release of the second contingent on outcomes from the ongoing ‘SEALS’ phase 2 clinical trial.